Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.

"compared with those treated with vedolizumab patients who received a cni or antimetabolite tended to have slightly lower grade toxicity but were otherwise largely similar ( online supplemental table 1 ) 10 1136/jitc-2023-008232 supp1 supplementary data 10 1136/jitc-2023-008232 supp2 supplementary data of 78 patients47 (60%) developed recurrent or progressive disease exploratory efs and os outcomes by post infliximab treatment and toxicity resolution are shown in figure 3a-d ."

"Competing interests: JMQ – Advisory board for BMS, Roche, Merck. AA – Reported honoraria, advisory/consultancy, speaker bureau/expert testimony, travel/accommodation/expenses from Pierre-Fabre, Novartis, MSD, BMS, Amgen, Merck, Sanofi and Eisai Ltd. CB – Reports grants from Advisory role: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures. Research funding: BMS, Novartis, NanoString. Stockownership: Uniti Cars, co-founder Immagene BV, all outside the submitted work. MSC - Advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre, Amgen, Ideaya, Merck Serono and Sanofi. DBJ – Advisory boards for Array Biopharma, BMS, Iovance, Jansen, Merck, Novartis, and Oncosec; Receives research grants from BMS and Incyte. GVL - consultant advisor for Aduro Biotech Inc, Amgen Inc, Array Biopharma Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Highlight Therapeutics S.L., Merck Sharp & Dohme, Novartis Pharma AG, Pierre Fabre, QBiotics Group Limited, Regeneron Pharmaceuticals Inc. AMM – Advisory boards for BMS, MSD, Novartis, Roche, Pierre-Fabre, QBiotics. BS – Honoraria from MSD, BMS, SUN Pharma, Allmiral, Novartis; Advisory Board for MSD, BMS, Pierre Fabre Pharma, Sanofi; travel support from BMS, Novartis, Pierre Fabre Pharma; Research Funding from Novartis; all outside the submitted work. LZ - served as consultant and has received honoraria from BMS, MSD, Novartis, Pierre Fabre, Sanofi, and Sunpharma and travel support from MSD, BMS, Pierre Fabre, Sanofi, Sunpharma and Novartis, outside the submitted work. KY- support from NIHR RM/ICR Biomedical Research Centre for Cancer, Institutional research support: AVEO Pharmaceuticals, Eisai, Ultimovacs,Teaching/promotional meetings: BMS, Eisai, Ipsen. CH, JL, AM-E, JMK, SNL, LT, KJN, NY, AT, YW and RMH report no disclosures."

"Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors."